Why the study?
Do new antiarrhythmic drugs safely treat cardiac arrhythmias without increasing mortality?
Do new antiarrhythmic drugs safely treat cardiac arrhythmias without increasing mortality?
Caution is advised when prescribing new antiarrhythmic drugs like flecainide and encainide due to proarrhythmic risks, pending results from mortality trials.
Answers are grounded in this paper and cite their sources.
Supports caution with flecainide and encainide for ventricular arrhythmias; leaves open mortality effects of new antiarrhythmics until trial data emerge.
Treatment of cardiac arrhythmia should be specifically aimed at symptom control or reduction in the risk of sudden cardiac death. Until recently, a limited number of antiarrhythmic drugs were available to the practicing physician, but during the last four years, seven new ones were approved. However, these drugs are complex and have different mechanisms of action and potential for adverse effects, so the safety of therapy with them continues to be debated. Although there is little doubt that many of the new drugs (particularly flecainide [Tambocor] and encainide [Enkaid]) are highly effective in suppressing ventricular premature complexes, they should be used with caution, since they also carry a potential for worsening arrhythmia (proarrhythmic effect) and congestive heart failure. Since suppression of arrhythmia has not yet been proven to reduce mortality, care must be taken in evaluating the risk-benefit ratio when prescribing therapy, particularly for patients with less malignant arrhythmias. Careful evaluation of the effects of treatment in individual patients is indicated whenever antiarrhythmic drugs are used. Until important mortality trials have been completed (eg, the Cardiac Arrhythmia Suppression Trial), therapy should be conservative and reserved for patients with severely symptomatic or malignant arrhythmias.
No takes yet. Share an insight, caveat, or question.
Jeffrey L. Anderson (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: